A phase II study of docetaxel and cisplatin as first-line chemotherapy in patients with metastatic nasopharyngeal carcinoma.
about
Metronomic oral cyclosphosphamide as third-line systemic treatment or beyond in patients with inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma.Phase II trial of capecitabine plus cisplatin as first-line therapy in patients with metastatic nasopharyngeal cancer.Triplet combination with paclitaxel, cisplatin and 5-FU is effective in metastatic and/or recurrent nasopharyngeal carcinoma.Treatment outcome of docetaxel, capecitabine and cisplatin regimen for patients with refractory and relapsed nasopharyngeal carcinoma who failed previous platinum-based chemotherapy.Radiotherapy combined docetaxel and oxaliplatin chemotherapy is effective in patients with locally advanced nasopharyngeal carcinoma.Phase II trial of docetaxel combined with nedaplatin for patients with recurrent and metastatic nasopharyngeal carcinomaAutophagy inhibition impairs the epithelial-mesenchymal transition and enhances cisplatin sensitivity in nasopharyngeal carcinoma.Development of synthetic of peptide-functionalized liposome for enhanced targeted ovarian carcinoma therapy.Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: current and future directions.The in vitro and in vivo effects of human umbilical cord mesenchymal stem cells on the growth of breast cancer cells.Preparation, characterization, and antitumor activity of paclitaxel-loaded folic acid modified and TAT peptide conjugated PEGylated polymeric liposomes.Effect of integrin receptor-targeted liposomal paclitaxel for hepatocellular carcinoma targeting and therapy.Plasma Epstein-Barr virus DNA level strongly predicts survival in metastatic/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy.Systemic therapies for recurrent or metastatic nasopharyngeal carcinoma: a systematic review.Docetaxel is effective in heavily pretreated patients with disseminated nasopharyngeal carcinoma.Development of synthetic of peptide-functionalized liposome for enhanced targeted ovarian carcinoma therapy
P2860
Q30846827-87914DD8-8740-4A47-A3C0-5AED1C68FBA8Q33398185-F978739E-3EF2-44A2-AD06-2DCB98D1C47EQ33404307-27ED05A9-A0DE-4231-820D-BFCF332DCDD0Q33411816-7D5D7922-0AE3-4EDF-9326-195CC47BD7BBQ33426763-4C4CD69D-D97D-4F77-9FB4-A69C33CCF71BQ33428455-0184D24B-E2BF-46C8-8D65-65D7868A1552Q33751245-D614BC90-B401-4D37-8752-250C95B3BC2AQ35016957-E7837B9B-F4EE-49CF-B7A2-38750404501AQ37171008-4B95A778-E8C5-4639-AFE5-47CA9D560E39Q39468118-B4223A99-CA1D-4510-8F48-DA1B50819F4AQ39672732-3A386459-CBA7-499C-8E8C-A3820679F914Q41110002-7DC3931E-D936-4CA8-BBF7-1E980C5D9534Q45369099-A986B87D-2916-4BC4-A3BF-06CC83418EB1Q47729318-54104E1E-EAD3-4AF0-AE9F-619B122FBAA1Q53065761-6A12AE61-8664-435E-9228-F9BFE57890F5Q56512260-C6BA0301-0F42-400B-BB6F-35704FBFDA50
P2860
A phase II study of docetaxel and cisplatin as first-line chemotherapy in patients with metastatic nasopharyngeal carcinoma.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
A phase II study of docetaxel ...... atic nasopharyngeal carcinoma.
@ast
A phase II study of docetaxel ...... atic nasopharyngeal carcinoma.
@en
type
label
A phase II study of docetaxel ...... atic nasopharyngeal carcinoma.
@ast
A phase II study of docetaxel ...... atic nasopharyngeal carcinoma.
@en
prefLabel
A phase II study of docetaxel ...... atic nasopharyngeal carcinoma.
@ast
A phase II study of docetaxel ...... atic nasopharyngeal carcinoma.
@en
P2093
P1433
P1476
A phase II study of docetaxel ...... atic nasopharyngeal carcinoma.
@en
P2093
Daniel T T Chua
Gordon K H Au
Jonathan S T Sham
P304
P356
10.1016/J.ORALONCOLOGY.2005.01.008
P407
P577
2005-04-14T00:00:00Z